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OBJECTIVES: SIMpill is a medication adherence management system using cellular 
networks to provide real-time information about, and support to, patients on long 
term medication. The SIMpill system is described in detail. METHODS: A pilot was 
carried out from July 1, 2006 to April 12, 2007 in Cape Town, South Africa. Patients 
diagnosed with Tuberculosis were taken onto the pilot as they arrived at the clinics 
until the desired number of patients was achieved. Contrary to the standard DOTS 
protocol, patients were allowed to self medicate either at their homes or their places 
of work, supported by the SIMpill system. RESULTS: Of the 155 TB patients enrolled 
in the pilot study the following results were recorded: 12 patients (8%) did not have 
adequate documentation of outcomes at the end of the pilot and are excluded from 
the data. One patient (0.8%) was recorded as a sputum positive treatment failure. 
Seven patients (3.3%) interrupted their treatment whilst four patients transferred to 
other clinics or died during the pilot study. a total of 131 patients (91.6% including 
unrelated interruptions, 94.2% excluding unrelated interruptions) were recorded as 
successful treatments. This is contrasted with the background treatment success rate 
under the DOTS regimen of 76.4% at the same time in the same communities. 
CONCLUSIONS: It is concluded that the SIMpill system is practical to implement, 
could dramatically improve treatment success in TB patients and warrants further 
study, both in TB and other conditions.
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OBJECTIVES: Treatment adherence is a key issue in chronic infectious diseases such 
as Chronic Hepatitis C (CHC). The aim of the study was to develop two valid and 
feasible disease speciﬁ c questionnaires to assess adherence to treatment of CHC 
monoinfected patients and HCV/HIV co-infected patients. METHODS: Question-
naires development was carried out in two phases. In the ﬁ rst phase, a literature review 
was performed in order to identify factors closely related to treatment adherence. By 
means of a focus group, disease experts selected the items considered most likely to 
affect adherence from the initial list, then the chosen items underwent a qualitative 
analysis and were rephrased to make them suitable for inclusion in a questionnaire. 
The ﬁ rst version of the questionnaires was completed by 18 patients (8 monoinfected 
and 10 co-infected) in order to evaluate the comprehension of questions, response 
categories, questionnaires applicability and the patients’ opinion on the proposed 
questionnaires design. The questionnaires are currently being validated in the second 
phase, an ongoing prospective study including 1120 patients. RESULTS: The two 
questionnaires developed for monoinfected and for co-infected patients contained 11 
and 13 questions, respectively. Both questionnaires included two questions related to 
treatment adherence and questions about reasons of non-adherence. To date 843 
patients have been included in the prospective study; 71.9% are male, 77.1% are 
monoinfected patients, 22.9% co-infected and 63.0% of patients have baseline 
RNA-HCV > 800.000 UI/ml (62.1% monoinfected and 66.1% co-infected). The HCV 
genotype distribution is 74.8% G-1/4 and 25.7% G-2/3. The HIV positive patients 
receiving ART Therapy are 91.2%. CONCLUSIONS: The two disease speciﬁ c ques-
tionnaires developed to assess adherence to treatment showed feasibility and good 
comprehension by patients with HCV monoinfection and with HCV/HIV co-infection, 
respectively. Further validation is ongoing in a prospective study.
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OBJECTIVES: To ﬁ nd out the number of people infected with AIDS, the age group 
that was badly hit by this disease, the number of deaths and most important of all 
the adherence shown by the patient to the treatment regimen. METHODS: Study 
subjects: All the people living with HIV/AIDS who were started on Anti Retroviral 
Therapy at the District ART Centre, Udupi District from 1st July, 2008 to 31st June, 
2009. Case ﬁ les were reviewed from medical records section and required data was 
collected and analyzed using SPSS 11.5 version. RESULTS: Study included 946 cases 
of which majority were males 534 and 815 were in the age-group of 15–49. 836 were 
residents of Udupi District. CONCLUSIONS: All of them were started on ART and 
have been on treatment for atleast 3 months. More than 90% of the patients had 
adherence of more than 95%.
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OBJECTIVES: Since the introduction of conjugate vaccines against Haemophilus 
inﬂ uenza type b (Hib) and Streptococcus pneumonia, Neisseria meningitis is the 
leading cause of infant bacterial meningitis. HibMenCY is a new combination vaccine 
being developed for protection against meningococcal groups C and Y (MenCY) and 
Hib. This analysis compared the cost-effectiveness of a four dose HibMenCY vaccina-
tion strategy (2, 4, 6 and 12 months) to Hib vaccination (2, 4, 6 and 12 months) and 
to no Hib or MenCY vaccination from a public health perspective. METHODS: A 
Markov model was used to simulate lifetime events, predicting the likelihood of 
disease with and without speciﬁ c vaccinations. Costs and health consequences were 
built into the model to allow the prediction of lifetime costs and quality-adjusted 
life-years (QALYs). The model was populated with published data throughout, and 
one-way sensitivity analyses were undertaken when there was uncertainty about key 
parameter values. a discount rate of 3% annually was applied. RESULTS: For Hib-
MenCY vaccination relative to Hib alone, 13 additional cases per 100,000 treated 
patients would be prevented, resulting in an additional 104 QALYS saved. The addi-
tional HibMenCY vaccine program cost over Hib alone was $6.61M resulting in a 
cost/QALY of $63,701. For HibMenCY vaccination relative to no Hib or MenCY 
vaccination, 61 cases of meningitis were prevented per 100,000 treated patients, 
resulting in an additional 467 QALYS saved. The additional HibMenCY vaccine 
program cost was $3.14M resulting in a cost/QALY of $6738. CONCLUSIONS: 
When accounting for the ability of the HibMenCY vaccine to prevent infection from 
both pathogens this intervention is estimated to be highly cost-effective. If only the 
incremental beneﬁ t of MenCY is considered, the intervention would result in a better 
cost/QALY than that reported for several widely implemented vaccine strategies. Thus 
infant HibMenCY vaccination is expected to be a cost-effective strategy that provides 
substantial health beneﬁ ts.
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OBJECTIVES: To elicit patient preferences for beneﬁ ts, risks, and weight of evidence 
associated with hepatitis B treatments. METHODS: Adults in 5 countries (France, 
Germany, Spain, Italy, and Turkey) with a self-reported physician diagnosis of hepa-
titis B completed a web-enabled, choice-format, conjoint-analysis survey. The survey 
presented patients with a series of 12 trade-off questions, each including a pair of 
hypothetical hepatitis B medication proﬁ les. Each proﬁ le was deﬁ ned by how long the 
medicine has been studied (weight of evidence), chance that the medicine will work 
well for 5 years (long-term efﬁ cacy), 5-year fracture risk, 5-year risk of kidney disease, 
and cost. Trade-off questions were based on predetermined experimental design with 
known statistical properties. Random-parameters logit was used to estimate a prefer-
ence weight for each attribute level and the mean relative importance of each attribute. 
RESULTS: 560 subjects completed the survey. Patients actively traded between efﬁ -
cacy, side-effect risks, and weight of evidence among the hypothetical hepatitis B 
medication proﬁ les. On an importance-weight scale where 0 is the least important 
outcome and 10 is the most important outcome, the 5-year risk of kidney disease was 
the most important attribute to patients over the range of levels included in the survey 
[95% CI: 7.8–12.2]. The remaining attributes were ranked in decreasing order of 
importance as: chance that the medicine will work well for 5 years (8.9 [95%CI: 
7.1–10.7]), how long the medicine has been studied (8.2 [95%CI: 7.6–8.8]), and 
5-year fracture risk (5.8 [95%CI: 3.6–8.0]). CONCLUSIONS: Although long-term 
efﬁ cacy is important to hepatitis B patients, the 5-year risk of kidney disease,in par-
ticular, also inﬂ uence patients’ treatment choices. Patients are willing to make trad-
eoffs between efﬁ cacy, side-effect risks, and weight of evidence among hepatitis B 
treatments.
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OBJECTIVES: The pain and discomfort associated with Herpes Zoster (HZ) and 
Post-Herpetic Neuralgia (PHN) can have a substantial negative impact on patients’ 
